Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Spotlight on Ozempic (Semaglutide): Ozempic, one of the most popular GLP-1 medications, contains semaglutide as its active ingredient and is administered as a convenient once-weekly injection
Pancreatic mucinous cystic neoplasms following GLP-1 receptor agonists use: a report of two cases with literature review
The "arms race" is shifting from who has the best drug to who can deliver the most convenient, affordable, and accessible treatment to a global population of over one billion people with obesity
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
We strongly believe that food needs to provide comfort and energy to ones life and not take away from it
